Rodriguez, MartaAlonso-Alonso, RuthTomas-Roca, LauraRodriguez-Pinilla, Socorro M.Manso-Alonso, RebecaCereceda, LauraBorregon, JenniferVillaescusa, TeresaCordoba, RaulSanchez-Beato, MargaritaFernandez-Miranda, IsmaelBetancor, IsabelBarcena, CarmenGarcia, Juan F.Mollejo, ManuelaGarcia-Cosio, MonicaMartin-Acosta, PalomaCliment, FinaCaballero, Doloresde la Fuente, LorenaMinguez, PabloKessler, LindaScholz, CatherineGualberto, AntonioMondejar, RufinoPiris, Miguel A.2025-01-072025-01-072021-12-202473-9529https://hdl.handle.net/10668/25153Peripheral T-cell lymphoma (PTCL) is a clinically aggressive disease, with a poor response to therapy and a low overall survival rate of approximately 30% after 5 years. We have analyzed a series of 105 cases with a diagnosis of PTCL using a customized NanoString platform (NanoString Technologies, Seattle, WA) that includes 208 genes associated with T-cell differentiation, oncogenes and tumor suppressor genes, deregulated pathways, and stromal cell subpopulations. A comparative analysis of the various histological types of PTCL (angioimmunoblastic T-cell lymphoma [AITL]; PTCL with T follicular helper [TFH] phenotype; PTCL not otherwise specified [NOS]) showed that specific sets of genes were associated with each of the diagnoses. These included TFH markers, cytotoxic markers, and genes whose expression was a surrogate for specific cellular subpopulations, including follicular dendritic cells, mast cells, and genes belonging to precise survival (NF-kappa B) and other pathways. Furthermore, the mutational profile was analyzed using a custom panel that targeted 62 genes in 76 cases distributed in AITL, PTCL-TFH, and PTCL-NOS. The main differences among the 3 nodal PTCL classes involved the RHOA(G)(17V) mutations (PenAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/ExpressionSurvivalMutationPeripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markersresearch article34592752open access10.1182/bloodadvances.20210051712473-9537https://ashpublications.org/bloodadvances/article-pdf/5/24/5588/1853862/advancesadv2021005171.pdf738846500015